News

FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca
Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.
PharmExec2d
FDA Approves Expanded Indication for Moderna’s Respiratory Syncytial Virus Vaccine mRESVIA
RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...
STAT6d
Merck’s RSV antibody treatment for infants is approved by FDA
The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.
CIDRAP5d
FDA approves Merck RSV monoclonal antibody shot for infants
Merck announced yesterday that the US Food and Drug Administration (FDA) has approved its monoclonal antibody vaccine ...
Zacks.com on MSN6d
Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants
MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.
WXYZ4d
FDA Approves Merck’s Enflonsia to prevent RSV in infants
The Food and Drug Administration has approved a new drug from Merck designed to protect infants ... their mothers did not receive a maternal RSV vaccine.